Analgesics (MCP-5064) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the worldwide markets for Analgesics in US$ Million by the following segments: Internal Analgesics, (Aspirin, Acetaminophen, Ibuprofen, and Others (includes combination drugs)), and External Analgesics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 137 companies including many key and niche players such as Bayer Consumer Care, Johnson & Johnson, McNeil Consumer Healthcare, Novartis International AG, Pfizer, Inc., Reckitt Benckiser Group Plc, and Sanofi Aventis S.A. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code :	MCP-5064
Price :	$4500
Companies :	137

Pages :	767
Date :	October 2010
Market Data Tables :	81

Complimentary Copy of Study Findings:

Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.

ANALGESICS (Complete Report)

Pages : 767

$4500

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......1

$295

Study Reliability and Reporting Limitations.......1

Disclaimers.......2

Data Interpretation & Reporting Level.......2

Quantitative Techniques & Analytics.......3

Product Definitions and Scope of Study.......3

1. Internal Analgesics.......3

Aspirin.......3

Acetaminophen.......3

Ibuprofen.......4

Others.......4

2. External Analgesics.......4

2. GLOBAL ANALGESICS MARKET OVERVIEW........5

$295

Pain Therapeutic Market........5

Analgesics Market - Offering Immense Potential........5

Internal Analgesics – The Largest & Fastest Growing Market........5

$100

Liquid Analgesics Register Rapid Growth........6

Neuropathic Pain - Unexplored........6

Ibuprofen Scoring High........6

External Analgesics – Loosing Sheen........6

$100

Topical Analgesics Market: Current Picture........7

Competitive Scenario........7

Global Analgesics Market (2007): Leading Analgesics Brands by Manufacturer........7

$100

3. PRODUCT OVERVIEW........8

$950

A Brief History........8

Analgesics........8

Definition........8

Types of Pain........8

Acute Pain........8

$100

Chronic Pain........9

Drugs Combating Pain........9

Local Anesthetics........9

$100

Narcotic Opioids........10

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)........10

Types of NSAIDS........10

$100

Common NSAIDs........11

$100

Clinical Use...........12

Side Effects...........12

$100

Aspirin........13

The Wonder Drug...........13

PolyAspirin: The Safer and More Potent Polymer Variant of Aspirin........13

Mode of Action........13

$100

Contraindications........14

Acetaminophen........14

Acetaminophen Protects Heart Muscle........14

$100

Acetaminophen Reduces Incidence of Ovarian Cancer........15

Ibuprofen, Ketoprofen and Naproxen........15

Combination Analgesics........15

$100

Table 1: Opioid Analgesics Market: Percentage Share of Opioid / Acetaminophen Combination Products in the Opioid Script Volume (includes corresponding Graph/Chart)........16

OTC Analgesics: An Overview........16

$350

4. INDUSTRY DYNAMICS........17

Escalating R&D Costs: A Boon or Bane?........17

Timeline of the Drug Approval Process........17

Cox II Crisis Tarnishes Industry Growth........17

$100

Novel Therapies to Propel Opioid and Non-Opioid Therapies........18

Rx-to-OTC Switch........18

Why Consumers Prefer OTC Drugs?........18

Development of Analgesic Tripeptides........18

$100

5. RECENT CLINICAL TRIALS........19

PLx Initiates Clinical Trial For Aspirin-PC........19

Neurodiscovery Receives Approval for NSL-101 Phase II Clinical Trials........19

$100

6. PRODUCT INTRODUCTIONS/INNOVATIONS........20

$295

Victory Pharma Unveils Naprelan Dose Card........20

Nutra Pharma Commences Online Sales of Cobroxin........20

Nutra Pharma to Introduce Nyloxin Rx........20

Dr Reddy’s Rolls Out Finrid........20

$100

MIP Technologies and Supelco Introduce Unique SPE Product........21

Novartis Introduces Voltaren AC Product Line........21

ProEthic Pharmaceuticals Releases Ibudone for Acute Pain Management........21

Dr. Reddy’s Laboratories Introduces Supanac for Acute Pain Management........21

$100

Teva Pharmaceutical Announces the Launch of Fentanyl Transdermal System........22

Dr. Reddy's Laboratories Introduces Supanac NSAID Drug........22

$100

7. PRODUCT INNOVATIONS/LAUNCHES IN RECENT PAST - A PERSPECTIVE BUILDER........23

Mallinckrodt Introduces Magnacet™ Tablets for Pain Management........23

Wockhardt to Launch New Painkiller........23

Paladin Labs and Labopharm Introduce Tridural™........23

Shionogi & Co Introduces OxiNorm Powder 0.5%........23

McNeil Brings Chewable TYLENOL® GoTabs Tablets........23

$100

Barr Unveils Generic Version of ACTIQ®........24

Novartis Launches Voltarol Pain-Eze Emulgel.........24

TheraQuest Launches TQ-1017........24

Mentholatum Company Introduces WellPatch Deep Heat Patch ........24

$100

8. PRODUCT APPROVALS........25

Par Pharmaceutical Secures Approval for Marketing Tramadol ER........25

Cipher Acquires Tentative Approval for Tramadol ER Capsules........25

Lannett Receives Approval for Developing Hydromorphone Hydrochloride Tablets........25

King Pharmaceuticals Receives Approval for Embeda Pain-Relief Capsules........25

$100

Sangart Secures EC’s Orphan Drug Designation for MP4CO........26

Biovail Secures Canadian Approval for Ralivia........26

Elite Pharmaceuticals and PharmaNetwrok Receive FDA Approval........26

$100

9. RECENT INDUSTRY ACTIVITY........27

$950

China Life Insurance Inks Agreement with Sino Biopharmaceutical........27

Azur Pharma Inks Agreement with Elan Pharmaceuticals........27

Pfizer Acquires Wyeth........27

Taisho Pharmaceutical Takes Over OTC Drugs Business of Bristol-Myers Squibb........27

$100

Piramal Healthcare Acquires Minrad International........28

Biocon Acquires Bulk Pharmaceuticals Unit of Hindujas........28

Abbott Acquires PG110 from PanGenetics........28

Sanofi-aventis Mexico Takes Over Laboratorios Kendrick........28

WraSer Acquires e5 Pharma’s Trezix........28

$100

Astellas Acquires Exclusive rights to Pain-Relief Drug from Neuroges........29

Henan Lingrui Pharma Commences Construction of New Analgesic Factory........29

Labopharm Europe Enters into Agreement with Merck Sharp & Dohme........29

Cumberland Pharmaceuticals Enters into a Commercialization Agreement with DB Pharm

Korea........29

$100

Cumberland Pharmaceuticals Inks an Exclusive Agreement with Phebra........30

Mallinckrodt Acquires Rights of Exalgo Extended-Release Tablets from Neuromed........30

Labopharm Europe and Grunenthal Sign Distribution and Supply Agreement........30

Timm Medical and Ferring Co-promote Prosed DS in the US........30

$100

Competitive Technologies and Fintrade Medical Ink Sales and Distribution

Agreement........31

Accumetrics and Endotech Ink Exclusive Distribution Agreement........31

Astellas and NeurogesX Sign Distribution and Marketing Agreement........31

Akela Pharma Inks Agreement with Teikoku Seiyaku........31

$100

Medical Nutrition Inks Exclusive Licensing Agreement with DSE Healthcare........32

Echo Therapeutics Inks a Licensing Deal with Ferndale Pharma........32

$100

Circ Pharma Signs a Development Agreement with Elan........33

Orexo Inks Distribution Agreement with Neopharm........33

Orexo Inks Agreement with NovaMed Pharmaceuticals........33

Pharmos and Reperio Enter into Agreement........33

$100

Caraco Pharmaceutical Launches Oxycodone Hydrochloride Tablet........34

Purdue Pharma Provides Labopharm’s RYZOLT........34

Bayer Acquires Sagmel’s OTC Business........34

E5 Pharma Receives Approval from FDA........34

Pharmaceutical Associates Receives Approval from FDA........34

$100

Concord Receives New Drug Approvals........35

Hisamitsu Receives Approval for SALONPAs®........35

Johnson & Johnson Submits NDA to FDA........35

Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural........35

Akela Extends Agreement with Janssen........35

Daiichi and Lead Chemical Receives Approval for Loxonin? Tape........35

$100

Tokio Marine Capital Acquires Showa Yakuhin Kako........36

Corgenix Collaborates with Randox Laboratories........36

Corgenix Receives EPO Approval for Aspirin Resistance Method........36

IOL to Expand Production Capacity........36

American Oriental Bioengineering Partners with China Aoxing........36

Abraxis Takes Over Shimoda and its Subsidiary Company........36

$100

Church & Dwight Snaps Up Del Pharmaceuticals from Coty........37

Sosei Group Corp Re-Acquires Rights to Commercialize AD 923........37

ProStrakan Group Inks Agreement with Paladin Labs........37

$100

Anika Therapeutics Inks Distribution Agreement with DePuy Mitek........38

Wyeth Acquires ThermaCare Brand from P&G........38

Albemarle Appoints Dr. Reddy’s as Distributor of Bulk Ibuprofen API........38

$100

Competitive Technologies and ELS Join Forces to Distribute Pain Management

Device........39

Altea Therapeutics Partners with Hospira........39

Paladin Inks Co-Promotion Deal with Nycomed........39

$100

AstraZeneca to Divest OTC Portfolio........40

$100

10. CORPORTAE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER........41

$395

Ranbaxy Receives Approval from FDA........41

Wockhardt Receives FDA Approval for DPN + APAP........41

Alpharma to Market Flector® Patch in the US........41

Auriga and Mikart Inks Agreement to Market Codein........41

Watson Receives FDA Approval for Oxycodone Hydrochloride and Ibuprofen........41

Labopharm’s Tramadol Receives Approval in Canada........41

$100

Lion Acquires BUFFERIN® Trademark Rights........42

Grunenthal’s Extends Licensing Agreement with Ortho-McNeil........42

China Aoxing Pockets LRT........42

Anesiva Inks Joint Venture Agreement Wanbang........42

Beijing Med-Pharm Inks Agreement with Lotus Healthcare........42

$100

LAB International Inks Licensing Agreement with Janssen Pharmaceutica........43

Three Sixty Pockets Rockford-Montgomery Labs........43

Antares Enters into License and Development Agreement for Opioid Analgesic........43

Abraxis BioScience Acquires AstraZeneca’s Analgesic Brand Portfolio........43

IntelliPharmaCeutics Inks Agreement with Larasan........43

$100

Ranbaxy and Ethypharm Ink In-licensing Agreement........44

Elite Collaborates with TPN to Co-develop Analgesic Drug........44

Novartis Acquires Hexal Company and Major Stake in Eon Labs .........44

NovaDel Pharma Receives Patent for Buccal Sprays Technology........44

Auxilium Pharmaceuticals Enters into a Licensing Agreement with PharmaForm ........44

$100

EC Sanctions Sale of Elan’s Prialt........45

EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc........45

Reckitt Benckiser plc Acquires Boots Healthcare International ........45

$100

11. FOCUS ON SELECT KEY PLAYERS........46

Bayer Consumer Care (US)........46

Johnson & Johnson (US)........46

McNeil Consumer Healthcare (Canada)........46

Novartis International AG (Switzerland)........46

$100

Pfizer Inc. (US)........47

Reckitt Benckiser Group Plc (UK)........47

Sanofi Aventis S.A. (France)........47

$100

12. GLOBAL MARKET PERSPECTIVE........48

Table 2: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........48

$350

Table 3: World Historic Review for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........49

$350

Table 4: World 11-Year Perspective for Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years2005,2010 & 2015(includes corresponding Graph/Chart)........50

$350

Table 5: World Recent Past, Current & Future Analysis for Internal Analgesics by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........51

$350

Table 6: World Historic Review for Internal Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........52

$350

Table 7: World 11-Year Perspective for Internal Analgesics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........53

$350

Table 8: World Recent Past, Current & Future Analysis for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........54

$350

Table 9: World Historic Review for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........55

$350

Table 10: World 11-Year Perspective for Internal Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Aspirin, Acetaminophen, Ibuprofen, and Others Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........56

$350

Table 11: World Recent Past, Current & Future Analysis for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........57

$350

Table 12: World Historic Review for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........58

$350

Table 13: World 11-Year Perspective for Aspirin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010& 2015 (includes corresponding Graph/Chart)........59

$350

Table 14: World Recent Past, Current & Future Analysis for Acetaminophen by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........60

$350

Table 15: World Historic Review for Acetaminophen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........61

$350

Table 16: World 11-Year Perspective for Acetaminophen by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010 & 2015 (includes corresponding Graph/Chart)........62

$350

Table 17: World Recent Past, Current & Future Analysis for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........63

$350

Table 18: World Historic Review for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........64

$350

Table 19: World 11-Year Perspective for Ibuprofen by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010 & 2015 (includes corresponding Graph/Chart)........65

$350

Table 20: World Recent Past, Current & Future Analysis for Other Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........66

$350

Table 21: World Historic Review for Other Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........67

$350

Table 22: World 11-Year Perspective for Other Internal Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years2005,2010 & 2015 (includes corresponding Graph/Chart)........68

$350

Table 23: World Recent Past, Current & Future Analysis for External Analgesics by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 2015 (includes corresponding Graph/Chart)........69

$350

Table 24: World Historic Review for External Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2007 (includes corresponding Graph/Chart)........70

$350

Table 25: World 11-Year Perspective for External Analgesics by Geographic Region /Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years2005,2010 & 2015(includes corresponding Graph/Chart)........71

$350

13. THE UNITED STATES........72

$1995

A. Market Analysis........72

Current and Future Analysis........72

Pain Statistics in the US........72

Industry Overview........72

$100

Internal Analgesics........73

Cox-2 Drugs in for Some Trouble........73

Switch to OTC Drugs........73

Table 26: US Analgesics Market (2009): Percentage Share Breakdown of Leading Manufacturers by Sales (includes corresponding Graph/Chart)........73

$350

Table 27: US Internal Liquid Analgesics Market (2009): Percentage Share Breakdown of Leading Brands by Sales (includes corresponding Graph/Chart)........74

Table 28: US Internal Tablet Analgesics Market (2009): Percentage Share Breakdown of Leading Brands by Sales (includes corresponding Graph/Chart)........74

$350

Table 29: Internal Analgesics Market in the US by Retail Channel (2008): Percentage Share by Value Sales for Discount Stores, Food/Drug Combination Stores, Chain Drug Stores, Supermarkets, and Independent Drug Stores (includes corresponding Graph/Chart)........75

Promotional Strategies for the Internal Analgesics........75

Table 30: Market for Internal Liquid Analgesics in the U.S. by Retail Channel (2008): Percentage Share by Value Sales for Supermarkets, Drug Stores, and Discounters (includes corresponding Graph/Chart)........75

Pediatric Analgesics: The New Kid on the Block........75

$350

External Analgesics........76

Stretching Boundaries........76

Table 31: US External Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart)........76

Table 32: External Analgesics Market in the US by Retail Channel (2008): Percentage Share by Value Sales for Chain drug stores, Discount stores, Food/drug combination stores, Independent drug stores, and Supermarkets (includes corresponding Graph/Chart)........76

$350

Rubs, Patches: Driving the External Analgesics Market........77

Patch Relief Gaining Momentum........77

B. Market Analytics........77

Table 33: US Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........77

$350

Table 34: US Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........78

$350

Table 35: US 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)........79

$350

14. CANADA........80

$950

Market Analysis........80

Table 36: Canadian Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........80

$350

Table 37: Canadian Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........81

$350

Table 38: Canadian 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)........82

$350

15. JAPAN........83

$950

A. Market Analysis........83

Current and Future Analysis........83

Competitive Scenario in the Past........83

Table 39: OTC Analgesics Market in Japan (2005): Market Share of Leading Players by Value – Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical, Shionogi, and Others (includes corresponding Graph/Chart)........83

$350

B. Market Analytics........84

Table 40: Japanese Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........84

$350

Table 41: Japanese Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........85

$350

Table 42: Japanese 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015 (includes corresponding Graph/Chart)........86

$350

16. EUROPE........87

$1995

A. Market Analysis........87

Current and Future Analysis........87

By Product Group/Segment........87

European Pain Management Market........87

Generics Restrain Revenue Growth........87

$100

Popular Brands in 2004........88

Table 43: Popular Brands of Pain & Inflammation Medication in Europe (2004): Percentage Share of Aspirin, Voltaren, Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin, and Paracetamol (includes corresponding Graph/Chart)........88

$350

B. Market Analytics........89

Table 44: European Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........89

$350

Table 45: European Historic Review for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........90

$350

Table 46: European 11-Year Perspective for Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........91

$350

Table 47: European Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........92

$350

Table 48: European Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2007 (includes corresponding Graph/Chart)........93

$350

Table 49: European 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........94

$350

16a. FRANCE........95

$950

A. Market Analysis........95

Current and Future Analysis........95

Competitive Scenario........95

Table 50: Analgesics Market in France (2005): Market Share of Leading Players by Value – Bristol-Myers Squibb, Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare, and Others) (includes corresponding Graph/Chart)........95

$350

B. Market Analytics........96

Table 51: French Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........96

$350

Table 52: French Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........97

$350

Table 53: French 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)........98

$350

16b. GERMANY........99

$950

A. Market Analysis........99

Current and Future Analysis........99

Competitive Scenario........99

Table 54: Analgesics Market in Germany (2005): Market Share of Leading Players by Value – Bayer Group, Boehringer Ingelheim, Wyeth Consumer Healthcare, and Others (includes corresponding Graph/Chart)........99

$350

B. Market Analytics........100

Table 55: German Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........100

$350

Table 56: German Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........101

$350

Table 57: German 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)........102

$350

16c. ITALY........103

$950

A. Market Analysis........103

Current and Future Analysis........103

Competitive Scenario........103

Table 58: Analgesics Market in Italy (2005): Market Share of Leading Players by Value – Bayer Group, Angelini, Novartis, Bristol-Myers Squibb, and Others (includes corresponding Graph/Chart)........103

$350

B. Market Analytics........104

Table 59: Italian Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........104

$350

Table 60: Italian Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........105

$350

Table 61: Italian 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015 (includes corresponding Graph/Chart)........106

$350

16d. THE UNITED KINGDOM........107

$950

A. Market Analysis........107

Current and Future Analysis........107

An Overview of Analgesics Market in the UK........107

Distribution Scenario........107

$100

Competitive Scenario........108

Table 62: Analgesics Market in the United Kingdom (2005E): Market Shares of Leading Players by Value – Boots Healthcare, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)........108

B. Market Analytics........108

Table 63: UK Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........108

$350

Table 64: UK Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........109

$350

Table 65: UK 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005,2010 & 2015(includes corresponding Graph/Chart)........110

$350

16e. SPAIN........111

$950

A. Market Analysis........111

Current and Future Analysis........111

Competitive Scenario........111

Table 66: Analgesics Market in Spain (2005): Market Share of Leading Players by Value – Bayer Group, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots Healthcare, and Others (includes corresponding Graph/Chart)........111

$350

B. Market Analytics........112

Table 67: Spanish Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........112

$350

Table 68: Spanish Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006(includes corresponding Graph/Chart)........113

$350

Table 69: Spanish 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015 (includes corresponding Graph/Chart)........114

$350

16f. REST OF EUROPE........115

$950

Market Analysis........115

Table 70: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........115

$350

Table 71: Rest of Europe Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........116

$350

Table 72: Rest of Europe 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........117

$350

17. ASIA-PACIFIC........118

$950

A. Market Analysis........118

Current and Future Analysis........118

The OTC Analgesic Market........118

OTC Analgesics Market in Asia-Pacific (2004): A Comparative Analysis of the Major

Regions – Australia, China and South Korea........118

$100

B. Market Analytics........119

Table 73: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)........119

$350

Table 74: Asia-Pacific Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........120

$350

Table 75: Asia-Pacific 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005,2010 & 2015(includes corresponding Graph/Chart)........121

$350

18. LATIN AMERICA........122

$950

Market Analysis........122

Table 76: Latin American Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........122

$350

Table 77: Latin American Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........123

$350

Table 78: Latin American 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)........124

$350

19. REST OF WORLD........125

$950

Market Analysis........125

Table 79: Rest of World Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........125

$350

Table 80: Rest of World Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)........126

$350

Table 81: Rest of World 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........127

$350

20. APPENDIX – POPULAR ANALGESIC BRANDS BY REGION........128

$950

Canada........128

France........128

$100

Germany........129

$100

United Kingdom........130

$100

Leading Analgesics Brands for Children........131

Italy........131

Spain........131

$100

Rest of Europe........132

$700

Asia-Pacific........139

$400

Latin America........143

$100

COMPETITION

610

$995

Total Companies Profiled: 137 (including Divisions/Subsidiaries - 179)
Region/Country                 Players

The United States                  47  
Canada                              5
Japan                               8
Europe                             62
     France                         4
     Germany                        9
     The United Kingdom            13
     Italy                          8
     Spain                          2
     Rest of Europe                22
Asia-Pacific (Excluding Japan)     49
Middle East                        10 
Africa                              2

Click here to request a full table of contents and more details on this project.

ANALGESICS - A GLOBAL STRATEGIC BUSINESS REPORT

Research Abstract

Complimentary Copy of Study Findings:

TABLE OF CONTENTS

ANALGESICS - A GLOBAL STRATEGIC BUSINESS REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Copy of Study Findings:

TABLE OF CONTENTS

ANALGESICS - A GLOBAL STRATEGIC BUSINESS REPORT